Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 17846 - catheter, intravascular, guiding - the apollo onyx delivery catheter is a single-lumen catheter designed to facilitate catheter retrieval in the event it becomes entrapped within the vasculature. the catheter has a semi-rigid proximal shaft which transitions into a flexible distal shaft. the distal section of the catheter incorporates a mechanical detachment zone that allows detachment of the tip when the force required to extract the catheter exceeds the force to detach the tip. the apollo microcatheter is intended to access the neurovasculature for the controlled selective infusion of clinician-specified therapeutics including embolisation materials and diagnostic agents such as contrast media.

India - Kiingereza - Central Drugs Standard Control Organization

flourish - ofloxacin,ornidazole - oz tab - 200,500;mg - 10

India - Kiingereza - Central Drugs Standard Control Organization

flourish - ofloxacin - tab - 10

Kanada - Kiingereza - Health Canada

akuna health products inc. - vitamin d3 (cholecalciferol); calcium (calcium phosphate); magnesium (magnesium oxide); manganese (manganese sulfate); silicon (silicon dioxide); zinc (zinc sulfate); selenium (sodium selenite); chromium (chromic chloride); molybdenum (sodium molybdate) - liquid - 200unit; 125mg; 200mg; 20mg; 9mg; 1mg; 3mcg; 0.5mcg; 0.05mcg - vitamin d3 (cholecalciferol) 200unit; calcium (calcium phosphate) 125mg; magnesium (magnesium oxide) 200mg; manganese (manganese sulfate) 20mg; silicon (silicon dioxide) 9mg; zinc (zinc sulfate) 1mg; selenium (sodium selenite) 3mcg; chromium (chromic chloride) 0.5mcg; molybdenum (sodium molybdate) 0.05mcg - vitamins & minerals

Falme za Kiarabu - Kiingereza - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

1 device(9590) -

Falme za Kiarabu - Kiingereza - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

metropolitan medical marketing sole proprietorship llc united states of america - 1 device(9590) - device - device - n/a

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd -

Singapoo - Kiingereza - HSA (Health Sciences Authority)

covidien private limited - neurology - intended to access the neuro vasculature for the controlled selective infusion of physician-specified therapeutic agents such as embolization materials and of diagnostic materials such as contrast media.

Marekani - Kiingereza - NLM (National Library of Medicine)

onyx pharmaceuticals, inc. - carfilzomib (unii: 72x6e3j5ar) (carfilzomib - unii:72x6e3j5ar) - carfilzomib 60 mg in 30 ml - - kyprolis is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with: lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. - lenalidomide and dexamethasone; or - dexamethasone; or - daratumumab and dexamethasone; or - daratumumab and hyaluronidase-fihj and dexamethasone; or - isatuximab and dexamethasone. - kyprolis is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. none. risk summary kyprolis can cause fetal harm based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1)] . there are no available data on kyprolis use in pregnant women to evaluate for drug-associated risks. kyprolis caused embryo-fetal lethality in rabbits at doses lower

Misri - Kiingereza - EDA (Egyptian Drug Authority)

onyx - topical ointment - 0.5 %